Skip to main content

Table 2 Comparison of principles provisions in AUSFTA, KORUS, and TPP

From: Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis

  AUSFTA KORUS TPP
Aims Facilitating high quality health care and continued improvements in public health Promoting the development of and facilitating access to high-quality patented and generic pharmaceutical products and medical devices, as a means of continuing to improve the health of their nationals. Facilitating high-quality health care and continued improvements in public health for their nationals, including patients and the public.
Areas
 Public health (a) the important role played by innovative pharmaceutical products in delivering high quality health care; (a) adequate access to pharmaceutical products and medical devices in providing high quality health care;
(b) patented and generic pharmaceutical products and medical devices in reducing other more costly medical expenditures;
(a) the importance of protecting and promoting public health and the important role played by pharmaceutical products and medical devices in delivering high-quality health care;
 Research & development (b) the importance of research and development in the pharmaceutical industry and of appropriate government support, including through intellectual property protection and other policies; (d) appropriate government support of research and development in academic and commercial laboratories, intellectual property protections, and other incentives for innovation in the research and development of pharmaceutical products and medical devices; (b) the importance of research and development, including innovation associated with research and development, related to pharmaceutical products and medical devices;
 Access (c) the need to promote timely and affordable access to innovative pharmaceuticals through transparent, expeditious, and accountable procedures (e) promoting innovation and timely and affordable access to safe and effective pharmaceutical products and medical devices through transparent and accountable procedures (c) the need to promote timely and affordable access to pharmaceutical products and medical devices, through transparent, impartial, expeditious and accountable procedures
 Value (d) the need to recognize the value of innovative pharmaceuticals through the operation of competitive markets or by adopting or maintaining procedures that appropriately value the objectively demonstrated therapeutic significance of a pharmaceutical. (c) sound economic incentives and competitive markets for the efficient development of and access to patented and generic pharmaceutical products and medical devices; (d) the need to recognise the value of pharmaceutical products and medical devices through the operation of competitive markets or by adopting or maintaining procedures that appropriately value the objectively demonstrated therapeutic significance of a pharmaceutical product or medical device.